Genetically elevated fetuin- A levels, fasting glucose levels, and risk of type 2 diabetes: The cardiovascular health study

Diabetes Care

Volumn 36, Issue 10, 2013, Pages 3121-3127

  Jensen, Majken K ^a   Bartz, Traci M ^b   Djousse, Luc ^c,d   Kizer, Jorge R ^e   Zieman, Susan J ^f   Rimm, Eric B ^a,g   Siscovick, David S ^h,i   Psaty, Bruce M ^h,i   Joachim, H ^j,k   Mukamal, Kenneth J ^l  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^f NATIONAL INSTITUTE ON AGING   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

^h UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

ⁱ CENTER FOR HEALTH STUDIES   (United States)

^j VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

FETUIN A; GLUCOSE;

AFRICAN AMERICAN; AGED; AHSG GENE; ARTICLE; CAUCASIAN; COMMUNITY LIVING; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ETHNIC DIFFERENCE; FEMALE; FOLLOW UP; GENE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GLUCOSE BLOOD LEVEL; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NULL ALLELE; PREVALENCE; SINGLE NUCLEOTIDE POLYMORPHISM; VERY ELDERLY;

ALPHA-2-HS-GLYCOPROTEIN; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FASTING; FEMALE; GENOTYPE; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 84891588697     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-2323     Document Type: Article

References (26)

1. Srinivas PR, Wagner AS, Reddy LV, et al. Serum alpha 2-HS-glycoprotein is an inhibitor of the human insulin receptor at the tyrosine kinase level. Mol Endocrinol 1993;7:1445-1455
2. Auberger P, Falquerho L, Contreres JO, et al. Characterization of a natural inhibitor of the insulin receptor tyrosine kinase: cDNA cloning, purification, and anti-mitogenic activity. Cell 1989;58: 631-640
3. Mathews ST, Srinivas PR, Leon MA, Grunberger G. Bovine fetuin is an inhibitor of insulin receptor tyrosine kinase. Life Sci 1997;61:1583-1592
4. Stefan N, Fritsche A, Weikert C, et al. Plasma fetuin-A levels and the risk of type 2 diabetes. Diabetes 2008;57:2762-2767
5. Ix JH, Wassel CL, Kanaya AM, et al.; Health ABC Study. Fetuin-A and incident diabetes mellitus in older persons. JAMA 2008;300:182-188
6. Ix JH, Biggs ML, Mukamal KJ, et al. Association of fetuin- A with incident diabetes mellitus in community-living older adults: the Cardiovascular Health Study. Circulation 2012;125:2316-2322
7. Vionnet N, Hani EH, Dupont S, et al. Genomewide search for type 2 diabetessusceptibility genes in French whites: evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome 1q21-q24. Am J Hum Genet 2000;67: 1470-1480
8. Kissebah AH, Sonnenberg GE, Myklebust J, et al. Quantitative trait loci on chromosomes 3 and 17 influence phenotypes of the metabolic syndrome. Proc Natl Acad Sci USA 2000;97:14478-14483
9. Siddiq A, Lepretre F, Hercberg S, Froguel P, Gibson F. A synonymous coding polymorphismin the alpha2-Heremans-schmid glycoprotein gene is associated with type 2 diabetes in French Caucasians. Diabetes 2005;54:2477-2481
10. Andersen G, Burgdorf KS, Sparsø T, et al. AHSG tag single nucleotide polymorphisms associate with type 2 diabetes and dyslipidemia: studies of metabolic traits in 7,683 white Danish subjects. Diabetes 2008;57:1427-1432
11. Osawa M, Tian W, Horiuchi H, Kaneko M, Umetsu K. Association of alpha2-HS glycoprotein (AHSG, fetuin-A) polymorphism with AHSG and phosphate serum levels. Hum Genet 2005;116:146-151
12. Fisher E, Stefan N, Saar K, et al. Association of AHSG gene polymorphisms with fetuin-A plasma levels and cardiovascular diseases in the EPIC-Potsdam study. Circ Cardiovasc Genet 2009;2: 607-613
13. Verduijn M, Prein RA, Stenvinkel P, et al. Is fetuin-A a mortality risk factor in dialysis patients or a mere risk marker? A Mendelian randomization approach. Nephrol Dial Transplant 2011;26:239-245
14. Stenvinkel P, Wang K, Qureshi AR, et al. Low fetuin-A levels are associated with cardiovascular death: Impact of variations in the gene encoding fetuin. Kidney Int 2005;67:2383-2392
15. Tell GS, Fried LP, Hermanson B, Manolio TA, Newman AB, Borhani NO. Recruitment of adults 65 years and older as participants in the Cardiovascular Health Study. Ann Epidemiol 1993;3: 358-366
16. Fried LP, Borhani NO, Enright P, et al. The Cardiovascular Health Study: design and rationale. Ann Epidemiol 1991;1: 263-276
17. Musunuru K, Lettre G, Young T, et al.; NHLBI Candidate Gene Association Resource. Candidate gene association resource (CARe): design, methods, and proof of concept. Circ Cardiovasc Genet 2010;3: 267-275
18. Keating BJ, Tischfield S, Murray SS, et al. Concept, design and implementation of a cardiovascular gene-centric 50 k SNP array for large-scale genomic association studies. PLoS ONE 2008;3:e3583
19. Cushman M, Cornell ES, Howard PR, Bovill EG, Tracy RP. Laboratory methods and quality assurance in the Cardiovascular Health Study. Clin Chem 1995;41: 264-270
20. Psaty BM, Lee M, Savage PJ, Rutan GH, German PS, Lyles M; The Cardiovascular Health Study Collaborative Research Group. Assessing the use of medications in the elderly: methods and initial experience in the Cardiovascular Health Study. J Clin Epidemiol 1992;45:683-692
21. Inoue M, Takata H, Ikeda Y, et al. A promoter polymorphism of the alpha2-HS glycoprotein gene is associated with its transcriptional activity. Diabetes Res Clin Pract 2008;79:164-170
22. Stock JH,Wright JH, Yogo M. A survey of weak instruments and weak identification in generalized method of moments. J Bus Econ Stat 2002;20:518-529
23. Sung KC, Jeong WS, Wild SH, Byrne CD. Combined influence of insulin resistance, overweight/obesity, and fatty liver as risk factors for type 2 diabetes. Diabetes Care 2012;35:717-722
24. Yilmaz Y, Yonal O, Kurt R, et al. Serum fetuin A/a2HS-glycoprotein levels in patients with non-alcoholic fatty liver disease: relation with liver fibrosis. Ann Clin Biochem 2010;47:549-553
25. Haukeland JW, Dahl TB, Yndestad A, et al. Fetuin A in nonalcoholic fatty liver disease: in vivo and in vitro studies. Eur J Endocrinol 2012;166:503-510
26. Kaess BM, Enserro DM, McManus DD, et al. Cardiometabolic correlates and heritability of fetuin-A, retinol-binding protein 4, and fatty-acid binding protein 4 in the Framingham Heart Study. J Clin Endocrinol Metab 2012;97:E1943-E1947